Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Psoriasis and Psoriatic Arthritis: How to Treat in the Era...
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Psoriasis and Psoriatic Arthritis: How to Treat in the Era of Biologics and Small Molecule Inhibitors: 3rd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 25 August 2025 | Viewed by 1495

Special Issue Editors

Dr. Mayumi Komine

E-Mail Website
Guest Editor
Department of Dermatology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
Interests: dermatology; keratinocyte biology; psoriasis; psoriatic arthritis; inflammatory reaction; ichthyosis
Special Issues, Collections and Topics in MDPI journals
Dr. Takemichi Fukasawa

E-Mail Website
Guest Editor
Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
Interests: systemic sclerosis; B cells; T cells; psoriasis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recent advancements have allowed us to use various biological drugs and small molecule inhibitors, such as JAK inhibitors and phosphodiesterase inhibitors, to treat psoriasis and psoriatic arthritis. We are now facing the question of how to best use these drugs, how to choose which to use, when to start, and for whom they should be used. Recent recommendations for psoriasis and psoriatic arthritis tell us that early intervention to prevent their development into deformities and/or functional defects is of importance and prevents cumulative impairment. It is difficult, however, to identify patients who would develop severe disease during the early phase of psoriasis with biologics or small molecule inhibitors. Recent research has started to reveal some clues about how to distinguish these patients, and we should include them in our daily clinics.

We previously launched the Special Issue “Psoriasis and Psoriatic Arthritis: How to Treat in the Era of Biologics and Small Molecule Inhibitors?” Volume 1 and Volume 2 (https://www.mdpi.com/journal/jcm/special_issues/Psoriasis_Psoriatic_Arthritis, https://www.mdpi.com/journal/jcm/special_issues/7QB0YO66H6), in which various important novel findings and review articles were published and attracted significant attention. Because of the substantial need for and special interest in this field, we decided to launch “Psoriasis and Psoriatic Arthritis: How to Treat in the Era of Biologics and Small Molecule Inhibitors: 3rd Edition” as a sequel to the previous Special Issue.

We welcome articles assessing and providing insights into the following issues: 1) how and when to treat psoriasis and psoriatic arthritis patients, 2) which patients need early intervention, 3) whether there are any disease markers that can be used to identify patients in need of early intervention, 4) how to detect early clinical signs of psoriatic arthritis, and 5) what dermatologists should do to address comorbid systemic disorders. We also welcome other topics related to psoriasis and psoriatic arthritis.

We welcome both review articles and research articles that present novel findings in this field and we hope to improve readers’ recognition of this systemic disease by presenting new understandings of it .

Dr. Mayumi Komine
Dr. Takemichi Fukasawa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • psoriatic arthritis
  • biologics
  • small molecule inhibitors
  • conventional therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issues

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1022 KiB  
Article
Comparative Analysis of Ixekizumab Effectiveness with and Without Induction Therapy in Moderate-to-Severe Psoriasis: A Real-World Study
by Ricardo Ruiz-Villaverde, Pedro José Ezomo-Gervilla, Jose Molina-Espinosa, Manuel Galán-Gutierrez, Enrique Herrera-Acosta and Jorge Alonso Suarez-Perez
J. Clin. Med. 2025, 14(3), 833; https://doi.org/10.3390/jcm14030833 - 27 Jan 2025
Viewed by 1126
Abstract
Background: Ixekizumab, an IL-17A inhibitor, is an effective treatment for moderate-to-severe plaque psoriasis. Although clinical trials support the use of an induction phase for optimal results, real-world evidence comparing induction versus maintenance-only regimens is limited. Objectives: This study assessed the real-world effectiveness, safety, [...] Read more.
Background: Ixekizumab, an IL-17A inhibitor, is an effective treatment for moderate-to-severe plaque psoriasis. Although clinical trials support the use of an induction phase for optimal results, real-world evidence comparing induction versus maintenance-only regimens is limited. Objectives: This study assessed the real-world effectiveness, safety, and drug survival of ixekizumab with and without an induction phase in patients with moderate-to-severe plaque psoriasis. Methods: A multicenter, observational study was conducted with 183 patients treated with ixekizumab over five years at tertiary hospitals in Andalucía, Spain. Patients were divided into two groups: an induction group (160 mg at baseline, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then every 4 weeks) and a non-induction group (80 mg every 4 weeks from initiation). Baseline characteristics, clinical outcomes (PASI [Psoriasis Activity Skin Index] and PGA [Physician Global Assessment] scores), and drug survival were analyzed. Results: The majority of patients were male (64.48% in the induction group, 58.74% in the non-induction group). No significant differences were found in age or BMI [body mass index] between groups. Baseline PASI and PGA scores were higher in the induction group, reflecting greater initial disease severity. Both regimens achieved significant clinical improvements, though the induction group demonstrated faster initial responses. Drug survival was lower in the induction group (p = 0.0033), potentially due to the higher baseline disease burden and severity in these patients. Comorbidities, including metabolic syndrome, cardiovascular risks, and psychiatric conditions, were prevalent, particularly in the induction group. Conclusions: Ixekizumab is effective for moderate-to-severe plaque psoriasis, with induction therapy yielding faster responses. However, lower drug survival in the induction group highlights the influence of initial disease severity on long-term outcomes. Real-world findings support the flexibility of ixekizumab across diverse patient populations, though further research is warranted. Full article
(This article belongs to the Special Issue Psoriasis and Psoriatic Arthritis: How to Treat in the Era of Biologics and Small Molecule Inhibitors: 3rd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop